Literature DB >> 29456664

Jinwei Tang modulates HDAC2 expression in a rat model of COPD.

Jianjun Wu1, Xin Li2, Yang Qin1, Juan Cheng3, Gaimei Hao4, Ruifeng Jin1, Chenjun Zhu5.   

Abstract

The aim of the present study was to investigate the effect of a Traditional Chinese Herbal Medicine (TCHM), named Jinwei Tang on histone deacetylase 2 (HDAC2) and its role in the regulation of corticosteroid resistance in a rat model of chronic obstructive pulmonary disease (COPD). Male Wistar rats were divided into five groups (each n=10): COPD group, established by the intratracheal instillation of lipopolysaccharide and passive smoke exposure, and control, budesonide, theophylline + budesonide and Jinwei Tang + budesonide groups. Lung function was measured, lung tissue histopathology was examined and HDAC2 expression in the lung was assessed by immunohistochemistry. In addition, protein levels of interleukin-8 (IL-8), tumor necrosis factor (TNF)-α and HDAC2 in lung homogenate were quantified by ELISA. The rat COPD model exhibited alterations of the ratio of forced expiratory volume in 0.2 sec (FEV0.2) to the forced vital capacity, FEV0.2, dynamic compliance and airway resistance. HDAC2 expression was markedly reduced in the lung tissue of the COPD group compared with the control group, and treatment with Jinwei Tang + budesonide or theophylline + budesonide resulted in significant attenuation of the reduction of HDAC2 expression in the lungs (P<0.05). However, treatment with budesonide alone did not significantly alter HDAC2 expression. In the Jinwei Tang + budesonide and theophylline + budesonide groups, IL-8 and TNF-α expression was significantly decreased (P<0.05) and the HDAC2 level increased (P<0.05) compared with that in the COPD group. In conclusion, Jinwei Tang modulates airway inflammation and may enhance the anti-inflammatory effect of glucocorticoid through the upregulation of HADC2 expression in a rat model of COPD.

Entities:  

Keywords:  chronic obstructive pulmonary disease; corticosteroid resistance; histone deacetylase; traditional Chinese herbal medicine

Year:  2018        PMID: 29456664      PMCID: PMC5795500          DOI: 10.3892/etm.2018.5707

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

Review 1.  Pathophysiology of exacerbations of chronic obstructive pulmonary disease.

Authors:  Alberto Papi; Fabrizio Luppi; Francesca Franco; Leonardo M Fabbri
Journal:  Proc Am Thorac Soc       Date:  2006-05

Review 2.  Pathogenesis of chronic obstructive pulmonary disease.

Authors:  William MacNee
Journal:  Proc Am Thorac Soc       Date:  2005

Review 3.  Glucocorticoid insensitivity as a source of drug targets for respiratory disease.

Authors:  Alaina J Ammit
Journal:  Curr Opin Pharmacol       Date:  2013-02-19       Impact factor: 5.547

4.  Liujunzi Tang, a famous traditional Chinese medicine, ameliorates cigarette smoke-induced mouse model of COPD.

Authors:  Rui Zhou; Fen Luo; Hui Lei; Kai Zhang; Jingyan Liu; He He; Jin Gao; Xiayun Chang; Ling He; Hui Ji; Tianhua Yan; Tong Chen
Journal:  J Ethnopharmacol       Date:  2016-09-19       Impact factor: 4.360

Review 5.  Development of new drugs for COPD.

Authors:  Peter J Barnes
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction.

Authors:  Amir Hakim; Ian M Adcock; Omar S Usmani
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

7.  Long-term effects of three Tiao-Bu Fei-Shen therapies on NF-κB/TGF-β1/smad2 signaling in rats with chronic obstructive pulmonary disease.

Authors:  Ya Li; Jian-sheng Li; Wei-wei Li; Su-yun Li; Yan-ge Tian; Xiao-fan Lu; Su-li Jiang; Ying Wang
Journal:  BMC Complement Altern Med       Date:  2014-04-26       Impact factor: 3.659

8.  Bufei Jianpi granules improve skeletal muscle and mitochondrial dysfunction in rats with chronic obstructive pulmonary disease.

Authors:  Yuqiong Dong; Ya Li; Yafei Sun; Jing Mao; Fengjia Yao; Yange Tian; Lili Wang; Linlin Li; Suyun Li; Jiansheng Li
Journal:  BMC Complement Altern Med       Date:  2015-03-10       Impact factor: 3.659

Review 9.  Safety of chinese herbal medicine for chronic obstructive pulmonary disease.

Authors:  Meaghan Coyle; Johannah Linda Shergis; Shaonan Liu; Lei Wu; Anthony Lin Zhang; Xinfeng Guo; Chuanjian Lu; Charlie Changli Xue
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-26       Impact factor: 2.629

10.  Histone modifications and traditional Chinese medicinals.

Authors:  Hsin-Ying Hsieh; Pei-Hsun Chiu; Sun-Chong Wang
Journal:  BMC Complement Altern Med       Date:  2013-05-27       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.